SI1572640T1 - Asimadolinski derivati, ki vsebujejo kovalentno vezane kisline - Google Patents

Asimadolinski derivati, ki vsebujejo kovalentno vezane kisline

Info

Publication number
SI1572640T1
SI1572640T1 SI200332242T SI200332242T SI1572640T1 SI 1572640 T1 SI1572640 T1 SI 1572640T1 SI 200332242 T SI200332242 T SI 200332242T SI 200332242 T SI200332242 T SI 200332242T SI 1572640 T1 SI1572640 T1 SI 1572640T1
Authority
SI
Slovenia
Prior art keywords
asimadoline
derivatives
covalently bonded
bonded acids
acids
Prior art date
Application number
SI200332242T
Other languages
English (en)
Slovenian (sl)
Inventor
Matthias Wiesner
Christoph Seyfried
Original Assignee
Tioga Pharmaceutcals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tioga Pharmaceutcals, Inc. filed Critical Tioga Pharmaceutcals, Inc.
Publication of SI1572640T1 publication Critical patent/SI1572640T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
SI200332242T 2002-12-17 2003-11-25 Asimadolinski derivati, ki vsebujejo kovalentno vezane kisline SI1572640T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10259245A DE10259245A1 (de) 2002-12-17 2002-12-17 Derivate des Asimadolins mit kovalent gebundenen Säuren
PCT/EP2003/013206 WO2004054970A1 (de) 2002-12-17 2003-11-25 Derivate des asimadolins mit kovalent gebundenen säuren
EP03780043A EP1572640B1 (de) 2002-12-17 2003-11-25 Derivate des asimadolins mit kovalent gebundenen saeuren

Publications (1)

Publication Number Publication Date
SI1572640T1 true SI1572640T1 (sl) 2013-03-29

Family

ID=32403913

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200332242T SI1572640T1 (sl) 2002-12-17 2003-11-25 Asimadolinski derivati, ki vsebujejo kovalentno vezane kisline

Country Status (14)

Country Link
US (3) US7385065B2 (enExample)
EP (1) EP1572640B1 (enExample)
JP (2) JP5253709B2 (enExample)
AU (1) AU2003288159B2 (enExample)
CA (1) CA2510167C (enExample)
CY (1) CY1113781T1 (enExample)
DE (1) DE10259245A1 (enExample)
DK (1) DK1572640T3 (enExample)
ES (1) ES2401876T3 (enExample)
PE (1) PE20040910A1 (enExample)
PT (1) PT1572640E (enExample)
SI (1) SI1572640T1 (enExample)
TW (1) TWI335815B (enExample)
WO (1) WO2004054970A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10259245A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
AU2004288641B2 (en) * 2003-10-30 2010-08-12 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
KR101208326B1 (ko) * 2007-03-30 2012-12-05 티오가 파마슈티칼스, 인코포레이티드 설사-우세형 및 교대형 과민성 장 증후군의 치료를 위한 카파-아편제 작용제
EP3013812B1 (en) 2013-06-28 2019-10-16 Nektar Therapeutics Kappa opioid agonists and uses thereof
CA3047325A1 (en) 2016-12-21 2018-06-28 Tioga Pharmaceuticals Inc. Solid pharmaceutical formulations of asimadoline
WO2019122361A1 (en) * 2017-12-22 2019-06-27 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Asimadoline for use in treating pulmonary diseases, vascular diseases, and sepsis
EP3932390A1 (en) 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760069A (en) * 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4889860A (en) * 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US5300687A (en) 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
DE4425071C2 (de) * 1994-07-15 1996-08-29 Degussa Verfahren zur Herstellung optisch aktiver Pyrrolidine mit hoher Enantiomerenreinheit
DE19523502A1 (de) * 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
US6303611B1 (en) 1996-03-08 2001-10-16 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
DE19647538A1 (de) 1996-11-16 1998-05-20 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[1-phenyl-2-(-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
CA2275167C (en) * 1996-12-16 2008-10-28 Alcon Laboratories, Inc. The topical use of kappa opioid agonists to treat ocular pain
EE200000386A (et) 1997-12-24 2001-12-17 Vertex Pharmaceuticals Incorporated Aspartüülproteaasi inhibiitorite eelravimid
DE19827633A1 (de) 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
DE19849650A1 (de) 1998-10-29 2000-05-04 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung des Irritable Bowel Syndroms (IBS)
US20020025948A1 (en) * 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB0015562D0 (en) 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) * 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
NZ526532A (en) * 2001-01-26 2005-01-28 Schering Corp The use of substituted azetidinone compounds for the treatment of sitosterolemia
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
AU2002364517A1 (en) 2001-11-30 2003-06-17 Sepracor Inc. Tramadol analogs and uses thereof
ES2325782T3 (es) * 2002-05-17 2009-09-17 Tioga Pharmaceuticals, Inc. Empleo de compuestos efectivos como moduladores selectivos de receptores de opiaceos.
DE10259245A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren

Also Published As

Publication number Publication date
WO2004054970A1 (de) 2004-07-01
US7915228B2 (en) 2011-03-29
EP1572640B1 (de) 2012-11-07
CA2510167C (en) 2011-05-24
AU2003288159A1 (en) 2004-07-09
PT1572640E (pt) 2013-02-15
EP1572640A1 (de) 2005-09-14
ES2401876T3 (es) 2013-04-25
DK1572640T3 (da) 2013-02-11
HK1080479A1 (en) 2006-04-28
US7385065B2 (en) 2008-06-10
JP2011157375A (ja) 2011-08-18
TW200418459A (en) 2004-10-01
US20060122255A1 (en) 2006-06-08
TWI335815B (en) 2011-01-11
AU2003288159B2 (en) 2010-05-20
US20070179098A1 (en) 2007-08-02
DE10259245A1 (de) 2004-07-01
CA2510167A1 (en) 2004-07-01
PE20040910A1 (es) 2004-12-02
JP5253709B2 (ja) 2013-07-31
CY1113781T1 (el) 2016-07-27
US20080234209A1 (en) 2008-09-25
JP2006511521A (ja) 2006-04-06

Similar Documents

Publication Publication Date Title
IL172617A0 (en) Biaryloxymethylarene-carboxylic acids
EP1517970A4 (en) BIOMEDICAL ADHESIVE
AU2003201850A1 (en) N-alkylsulfonyl-substituted amide derivatives
AU2003211362A1 (en) N-hydroxycarboxamide derivative
AU2003235913A1 (en) Cyanopyrrolidine derivatives
AU2003283542A1 (en) Proximity sensor
AU2003268670A1 (en) Joining apparatus
PT1572640E (pt) Derivados da asimadolina que compreendem ácidos ligados covalentemente
AU2003208719A1 (en) Chassis dynanometer
AU2003290216A1 (en) Porphyrin derivatives
AU2003226725A8 (en) Pyrazolopyrimidine derivatives
AU2003231370A1 (en) Amide derivatives
AUPS034702A0 (en) Trailer
AU2002328894A1 (en) Substituted 4-aminocyclohexanol derivatives
AU2003265845A1 (en) METHODS FOR THE PREPARATION OF Beta-AMINO ACIDS
AU2003235889A1 (en) Amide derivatives
AU2003301676A1 (en) Polyamides
GB2392914B (en) Adhesive for water-soluble packagings
AU2003227421A1 (en) Microbial-origin polyamino acids or derivatives thereof
EP1491564B8 (de) Polyisocyanat-modifizierte Polycarbonsäuren
AU2003281198A1 (en) m-PHENYLENEDIAMINE DERIVATIVE
AU2003221226A1 (en) Connecting unit for flat parts
AU2003224240A1 (en) Compounds comprising pseudo-amino acids
AU2002368547A1 (en) Methods of sterilizing with dipercarboxylic acids
GB0221188D0 (en) Joints